Luminal B Breast Cancer Prognosis

Group 2 luminal b.

Luminal b breast cancer prognosis.

Estrogen receptor er progesterone receptor pgr antigen identified by monoclonal antibody ki 67 ki67 were immunohistochemically detected. Clinical data of 695 luminal b like breast cancer patients who had been treated in our hospital during the period of past 4 5 years were collected and analyzed. This group includes tumors that are er positive and pr positive but negative for her2. Luminal tumor cells look like those of breast cancers that start in the inner luminal cells lining the mammary ducts.

Moreover the two er breast cancer subtypes luminal a and luminal b are linked with a good prognosis and excellent long term survival approximately 80 85 5 year survival whereas the er negative subtypes her2 and basal like are challenging to manage and are linked with poor prognosis approximately 50 60 5 year survival. Of the 4 major subtypes luminal a tumors tend to have the best prognosis with fairly high survival rates and fairly low recurrence rates. Luminal a cancers are low grade tend to grow slowly and have the best prognosis. This study aimed to examine the prognostic factors of luminal b like breast cancer.

Luminal type breast cancer showed better prognosis than other subtypes and additionally when we divide luminal type breast cancer to types a and b by ki 67 expression cutoff value 14 luminal type a ki 67 14 breast cancer showed a lower relapse risk and a longer survival period than luminal type b ki 67 14 breast cancer. In our study young patients with luminal b breast cancer had a 2 5 fold higher risk of death and 3 6 fold higher risk of relapse disease compared with the older counterpart luminal a her2 or triple negative had similar survival outcomes in the two age groups. The risk of recurrence and metastasis in patients with luminal b breast cancer during a 2 to 5 year period and after 5 years was still present but the risk in patients with non luminal breast. Luminal b breast cancer is hormone receptor.

Breast cancer groups include. Luminal a tumors are associated with the most favorable prognosis. Luminal a breast cancer is hormone receptor positive estrogen receptor and or progesterone receptor positive her2 negative and has low levels of the protein ki 67 which helps control how fast cancer cells grow. These groups help guide decisions about which treatments are best.

Group 1 luminal a. Luminal a breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy. Breast cancer facts figures 2019 2020 3 luminal a hr her2. A 2019 review of breast cancer treatments features survival rates for different types of breast cancer.